OMB APPROVAL
|
OMB Number:3235-0070
Expires: April 30, 2015
Estimated average burden
hours per response 187.43
|
T
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED
March 31, 2013
.
|
Delaware
|
95-4302784
|
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer
Identification No.)
|
1229 Oak Valley Drive, Ann Arbor, Michigan
|
48108
|
|
(Address of principal executive offices)
|
(Zip Code)
|
(800) 281-0356
|
(Registrant’s telephone number, including area code)
|
(Former name, former address and former fiscal year, if changed since last report)
|
Item
|
Page
|
|
PART I - FINANCIAL INFORMATION
|
||
3 | ||
3
|
||
5
|
||
6
|
||
8
|
||
13
|
||
16
|
||
17
|
||
PART II - OTHER INFORMATION
|
||
18
|
||
18
|
||
21
|
||
22
|
ITEM
1.
|
FINANCIAL STATEMENTS (UNAUDITED)
|
March 31,
2013
|
December 31,
2012
|
|||||||
ASSETS
|
||||||||
CURRENT ASSETS:
|
||||||||
Cash and cash equivalents
|
$ | 377,812 | $ | 1,580,627 | ||||
Restricted collateral deposits
|
489,253 | 186,306 | ||||||
Trade receivables
|
14,329,246 | 9,639,709 | ||||||
Unbilled receivables
|
12,480,827 | 13,374,004 | ||||||
Other accounts receivable and prepaid expenses
|
1,027,490 | 1,178,780 | ||||||
Inventories
|
10,461,815 | 10,033,525 | ||||||
Discontinued operations – short term
|
122,310 | 389,272 | ||||||
Total current assets
|
39,288,753 | 36,382,223 | ||||||
LONG TERM ASSETS:
|
||||||||
Severance pay fund
|
4,603,249 | 4,177,488 | ||||||
Other long term receivables
|
56,441 | 55,156 | ||||||
Property and equipment, net
|
5,070,771 | 4,464,580 | ||||||
Other intangible assets, net
|
1,953,037 | 2,238,273 | ||||||
Goodwill
|
30,705,052 | 30,562,298 | ||||||
Total long term assets
|
42,388,550 | 41,497,795 | ||||||
Total assets
|
$ | 81,677,303 | $ | 77,880,018 |
March 31,
2013
|
December 31,
2012
|
|||||||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
CURRENT LIABILITIES:
|
||||||||
Trade payables
|
$ | 8,307,264 | $ | 7,156,327 | ||||
Other accounts payable and accrued expenses
|
3,637,849 | 4,252,910 | ||||||
Current portion of long term debt
|
334,063 | 888,839 | ||||||
Short term bank credit
|
11,991,501 | 9,787,779 | ||||||
Deferred revenues
|
4,540,544 | 3,798,086 | ||||||
Discontinued operations – short term
|
100,407 | 588,592 | ||||||
Total current liabilities
|
28,911,628 | 26,472,533 | ||||||
LONG TERM LIABILITIES: | ||||||||
Accrued severance pay
|
6,627,879 | 6,133,042 | ||||||
Long term portion of debt
|
1,003,750 | 992,917 | ||||||
Deferred tax liability
|
5,069,646 | 4,920,021 | ||||||
Other long-term liabilities
|
26,507 | 27,590 | ||||||
Discontinued operations – long term
|
902,774 | 912,813 | ||||||
Total long-term liabilities
|
13,630,556 | 12,986,383 | ||||||
STOCKHOLDERS’ EQUITY:
|
||||||||
Share capital –
|
||||||||
Common stock – $0.01 par value each;
Authorized: 50,000,000 shares as of March 31, 2013 and December 31, 2012; Issued and outstanding: 16,174,187 shares and 16,151,298 shares as of March 31, 2013 and December 31, 2012, respectively
|
161,742 | 161,513 | ||||||
Preferred shares – $0.01 par value each;
Authorized: 1,000,000 shares as of March 31, 2013 and December 31, 2012; No shares issued or outstanding as of March 31, 2013 and December 31, 2012
|
– | – | ||||||
Additional paid-in capital
|
223,279,772 | 223,181,705 | ||||||
Accumulated deficit
|
(184,844,878 | ) | (185,248,923 | ) | ||||
Notes receivable from stockholders
|
(908,054 | ) | (908,054 | ) | ||||
Accumulated other comprehensive income
|
1,446,537 | 1,234,861 | ||||||
Total stockholders’ equity
|
39,135,119 | 38,421,102 | ||||||
Total liabilities and stockholders’ equity
|
$ | 81,677,303 | $ | 77,880,018 |
Three months ended March 31,
|
||||||||
2013
|
2012
|
|||||||
Revenues
|
$ | 22,053,131 | $ | 16,107,708 | ||||
Cost of revenues
|
16,776,967 | 11,819,066 | ||||||
Research and development expenses
|
533,385 | 591,153 | ||||||
Selling and marketing expenses
|
1,237,006 | 1,284,894 | ||||||
General and administrative expenses
|
2,387,811 | 3,000,606 | ||||||
Amortization of intangible assets
|
276,494 | 301,371 | ||||||
Total operating costs and expenses
|
21,211,663 | 16,997,090 | ||||||
Operating income (loss)
|
841,468 | (889,382 | ) | |||||
Other income
|
1,233 | 192 | ||||||
Financial expense, net
|
(189,137 | ) | (36,836 | ) | ||||
Total other expense
|
(187,904 | ) | (36,644 | ) | ||||
Income (loss) from continuing operations before income tax expense
|
653,564 | (926,026 | ) | |||||
Income tax expense
|
174,777 | 197,577 | ||||||
Income (loss) from continuing operations
|
478,787 | (1,123,603 | ) | |||||
Income (loss) from discontinued operations, net of income tax
|
(74,743 | ) | 64,160 | |||||
Net income (loss)
|
404,044 | (1,059,443 | ) | |||||
Other comprehensive income, net of income tax
|
||||||||
Foreign currency translation adjustment
|
211,676 | 167,075 | ||||||
Comprehensive income (loss)
|
$ | 615,720 | $ | (892,368 | ) | |||
Basic net income/loss per share – continuing operations
|
$ | 0.03 | $ | (0.08 | ) | |||
Basic net income/loss per share – discontinued operations
|
– | 0.01 | ||||||
Basic net income/loss per share
|
$ | 0.03 | $ | (0.07 | ) | |||
Diluted net income/loss per share – continuing operations
|
$ | 0.03 | $ | (0.08 | ) | |||
Diluted net income/loss per share – discontinued operations
|
– | 0.01 | ||||||
Diluted net income/loss per share
|
$ | 0.03 | $ | (0.07 | ) | |||
Weighted average number of shares used in computing basic net income/loss per share
|
15,569,153 | 14,654,803 | ||||||
Weighted average number of shares used in computing diluted net income/loss per share
|
16,171,893 | 14,654,803 |
Three months ended March 31,
|
||||||||
2013
|
2012
|
|||||||
CASH FLOWS FROM OPERATING ACTIVITIES:
|
||||||||
Net income (loss)
|
$ | 404,044 | $ | (1,059,443 | ) | |||
Adjustments required to reconcile net income (loss) to net cash (used in) provided by operating activities:
|
||||||||
Depreciation
|
294,762 | 273,007 | ||||||
Amortization of intangible assets
|
276,494 | 301,371 | ||||||
Stock based compensation
|
98,295 | 63,203 | ||||||
Deferred tax provision
|
149,625 | 149,625 | ||||||
Changes in continuing operating assets and liabilities:
|
||||||||
Severance pay, net
|
69,076 | 43,877 | ||||||
Trade receivables
|
(4,689,537 | ) | 4,417,875 | |||||
Other accounts receivable and prepaid expenses
|
150,005 | 177,523 | ||||||
Inventories
|
(428,290 | ) | (344,719 | ) | ||||
Unbilled receivables
|
893,177 | (2,558,355 | ) | |||||
Deferred revenues
|
742,458 | (574,116 | ) | |||||
Trade payables
|
1,150,937 | (1,683,114 | ) | |||||
Other accounts payable and accrued expenses
|
(616,141 | ) | 91,249 | |||||
Discontinued operations
|
(323,725 | ) | 598,458 | |||||
Net cash provided by (used in) operating activities
|
(1,828,820 | ) | (103,559 | ) | ||||
CASH FLOWS FROM INVESTING ACTIVITIES:
|
||||||||
Purchase of property and equipment
|
(900,953 | ) | (302,876 | ) | ||||
Additions to capitalized software development
|
(3,675 | ) | – | |||||
Decrease (increase) in restricted collateral deposits
|
(302,947 | ) | 1,581,377 | |||||
Discontinued operations
|
44,827 | 54,553 | ||||||
Net cash provided by (used in) investing activities
|
$ | (1,162,748 | ) | $ | 1,333,054 |
Three months ended March 31,
|
||||||||
2013
|
2012
|
|||||||
CASH FLOWS FROM FINANCING ACTIVITIES:
|
||||||||
Repayment of long term debt
|
$ | (543,943 | ) | $ | (31,071 | ) | ||
Change in short term bank credit
|
2,203,722 | (1,202,964 | ) | |||||
Discontinued operations
|
(9,298 | ) | (331,711 | ) | ||||
Net cash provided by (used in) financing activities
|
1,650,481 | (1,565,746 | ) | |||||
DECREASE IN CASH AND CASH EQUIVALENTS
|
(1,341,087 | ) | (336,251 | ) | ||||
CASH ACCRETION (EROSION) DUE TO EXCHANGE RATE DIFFERENCES
|
81,339 | (13,566 | ) | |||||
NET CHANGE IN CASH AND EQUIVALENTS – DISCONTINUED OPERATIONS
|
56,933 | (250,392 | ) | |||||
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD
|
1,580,627 | 2,324,163 | ||||||
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD
|
$ | 377,812 | $ | 1,723,954 | ||||
SUPPLEMENTARY INFORMATION ON NON-CASH TRANSACTIONS:
|
||||||||
Interest paid during the period
|
$ | 73,871 | $ | 64,216 | ||||
Taxes paid on income during the period
|
$ | 10,500 | $ | – |
ASSETS AND LIABILITIES – DISCONTINUED
(UNAUDITED)
|
March 31,
2013
|
December 31,
2012
|
||||||
|
||||||||
ASSETS
|
||||||||
CURRENT ASSETS:
|
||||||||
Cash and cash equivalents
|
$ | 49,615 | $ | 106,548 | ||||
Restricted collateral deposits
|
– | 44,827 | ||||||
Trade receivables
|
40,961 | 164,824 | ||||||
Other accounts receivable and prepaid expenses
|
31,734 | 73,073 | ||||||
Total
current assets
|
122,310 | 389,272 | ||||||
Total assets
|
$ | 122,310 | $ | 389,272 | ||||
LIABILITIES
|
||||||||
CURRENT LIABILITIES:
|
||||||||
Trade payables
|
$ | – | $ | 75,862 | ||||
Other accounts payable and accrued expenses
|
40,379 | 453,443 | ||||||
Current portion of long term debt
|
60,028 | 59,287 | ||||||
Total current liabilities
|
100,407 | 588,592 | ||||||
LONG TERM LIABILITIES
|
||||||||
Long term debt (building mortgage)
|
902,774 | 912,813 | ||||||
Total long-term liabilities
|
902,774 | 912,813 | ||||||
Total liabilities
|
$ | 1,003,181 | $ | 1,501,405 |
REVENUE AND EXPENSES – DISCONTINUED
(UNAUDITED)
|
Three months ended March 31,
|
|||||||
2013
|
2012
|
|||||||
Revenues
|
$ | 1,954 | $ | 4,009,561 | ||||
Cost of revenues, exclusive of amortization of intangibles
|
(2,303 | ) | 3,472,323 | |||||
Research and development expenses
|
– | 50,358 | ||||||
Selling and marketing expenses
|
– | 183,080 | ||||||
General and administrative expenses
|
81,939 | 246,403 | ||||||
Total operating costs and expenses
|
79,636 | 3,952,164 | ||||||
Operating income (loss)
|
(77,682 | ) | 57,397 | |||||
Other income
|
27,986 | 21,281 | ||||||
Financial (income) expense, net
|
(24,047 | ) | (14,518 | ) | ||||
Total other income
|
3,939 | 6,763 | ||||||
Income (loss) before income tax
|
(73,743 | ) | 64,160 | |||||
Income tax expense
|
1,000 | – | ||||||
Net income (loss)
|
$ | (74,743 | ) | $ | 64,160 |
March 31,
2013
|
December 31,
2012
|
|||||||
(Unaudited)
|
(Unaudited)
|
|||||||
Raw and packaging materials
|
$ | 7,813,653 | $ | 7,455,426 | ||||
Work in progress
|
500,696 | 363,415 | ||||||
Finished products
|
2,147,466 | 2,214,684 | ||||||
Total:
|
$ | 10,461,815 | $ | 10,033,525 |
Training and
Simulation
Division
|
Battery and
Power Systems
Division
|
Corporate
Expenses
|
Discontinued
|
Total
Company
|
||||||||||||||||
Three months ended March 31, 2013
|
||||||||||||||||||||
Revenues from outside customers
|
$ | 15,679,191 | $ | 6,373,940 | $ | – | $ | – | $ | 22,053,131 | ||||||||||
Depreciation, amortization and impairment expenses
(1)
|
(243,994 | ) | (319,742 | ) | (7,520 | ) | – | (571,256 | ) | |||||||||||
Direct expenses
(2)
|
(13,426,464 | ) | (6,097,049 | ) | (1,115,661 | ) | – | (20,639,174 | ) | |||||||||||
Segment net income (loss)
|
$ | 2,008,733 | $ | (42,851 | ) | $ | (1,123,181 | ) | $ | – | $ | 842,701 | ||||||||
Financial income (expense)
|
(6,939 | ) | (61,440 | ) | (120,758 | ) | – | (189,137 | ) | |||||||||||
Income tax expense
|
25,152 | – | 149,625 | – | 174,777 | |||||||||||||||
Net income (loss) continuing operations
|
$ | 1,976,642 | $ | (104,291 | ) | $ | (1,393,564 | ) | $ | – | $ | 478,787 | ||||||||
Net income discontinued operations
|
– | – | – | (74,743 | ) | (74,743 | ) | |||||||||||||
Net income (loss)
|
$ | 1,976,642 | $ | (104,291 | ) | $ | (1,393,564 | ) | $ | (74,743 | ) | $ | 404,044 | |||||||
Segment assets
(3)
|
$ | 53,321,818 | $ | 27,685,266 | $ | 547,909 | $ | 122,310 | $ | 81,677,303 | ||||||||||
Additions to long-lived assets
|
$ | 31,604 | $ | 873,024 | $ | – | $ | – | $ | 904,628 | ||||||||||
Three months ended March 31, 2012
|
||||||||||||||||||||
Revenues from outside customers
|
$ | 10,933,538 | $ | 5,174,170 | $ | – | $ | – | $ | 16,107,708 | ||||||||||
Depreciation, amortization and impairment expenses
(1)
|
(279,763 | ) | (279,251 | ) | (15,364 | ) | – | (574,378 | ) | |||||||||||
Direct expenses
(2)
|
(10,072,542 | ) | (4,574,425 | ) | (1,775,553 | ) | – | (16,422,520 | ) | |||||||||||
Segment net income (loss)
|
$ | 581,233 | $ | 320,494 | $ | (1,790,917 | ) | $ | – | $ | (889,190 | ) | ||||||||
Financial income (expense)
|
(13,455 | ) | 57,670 | (81,051 | ) | – | (36,836 | ) | ||||||||||||
Income tax expense
|
47,952 | – | 149,625 | – | 197,577 | |||||||||||||||
Net income (loss) continuing operations
|
$ | 519,826 | $ | 378,164 | $ | (2,021,593 | ) | $ | – | $ | (1,123,603 | ) | ||||||||
Net income discontinued operations
|
– | – | – | 64,160 | 64,160 | |||||||||||||||
Net income (loss)
|
$ | 519,826 | $ | 378,164 | $ | (2,021,593 | ) | $ | 64,160 | $ | (1,059,443 | ) | ||||||||
Segment assets
(3)
|
$ | 44,708,798 | $ | 25,275,405 | $ | 875,500 | $ | 5,154,002 | $ | 76,013,705 | ||||||||||
Additions to long-lived assets
|
$ | 161,429 | $ | 141,447 | $ | – | $ | – | $ | 302,876 |
ITEM
2.
|
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
|
Ø
|
We develop, manufacture and market advanced high-tech multimedia and interactive digital solutions for use-of-force training and driving training of military, law enforcement, security and other personnel (our
Training and Simulation Division
); and
|
Ø
|
We manufacture and sell lithium and Zinc-Air batteries for defense and security products, including our Soldier Wearable Integrated Power Equipment System (SWIPES)™ power hubs, and other military applications (our
Battery and Power Systems Division
).
|
Three months ended March 31,
|
||||||||
Type of Revenue
|
2013
|
2012
|
||||||
Sale of products
|
95.7 | % | 96.1 | % | ||||
Maintenance and support agreements
|
2.8 | % | 3.2 | % | ||||
Long term research and development contracts
|
1.5 | % | 0.7 | % | ||||
Total
|
100.0 | % | 100.0 | % |
ITEM
3.
|
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
|
Exhibit Number
|
Description
|
|
10.1
|
||
10.2
|
||
10.3
|
||
10.4
|
||
31.1
|
||
31.2
|
||
32.1
|
||
32.2
|
AROTECH CORPORATION
|
||||
By:
|
/s/ Robert S. Ehrlich
|
|||
Name:
|
Robert S. Ehrlich
|
|||
Title:
|
Chairman and CEO
|
|||
(Principal Executive Officer)
|
By:
|
/s/ Thomas J. Paup
|
||
Name:
|
Thomas J. Paup
|
||
Title:
|
Vice President – Finance and CFO
|
||
(Principal Financial Officer)
|
(a)
|
The Executive shall be employed as the Chairman of the Board and Chief Executive Officer of Arotech until September 30, 2014, and thereafter shall be employed as Chairman of the Board of the Company. The Executive shall perform the duties, undertake the responsibilities and exercise the authority customarily performed, undertaken and exercised by persons situated in a similar executive capacity in publicly-held United States corporations and their Israeli subsidiaries. The Executive shall exercise his authority in a reasonable manner and shall report to the Board of Directors of each Company (each a “Board”).
|
(b)
|
Excluding periods of vacation and sick leave to which the Executive shall be entitled, the Executive agrees to devote the attention and time to the businesses and affairs of the Companies required to discharge the responsibilities assigned to the Executive hereunder. The Executive’s duties shall be in the nature of management duties that demand a special level of loyalty and accordingly the Israeli Law of Work Hours and Rest, 5711 - 1951 shall not apply to this Agreement.
|
(c)
|
While the Executive is employed by the Companies hereunder, Arotech shall use its best efforts to cause the Executive to be elected to, and if so elected the Executive shall serve on, the Board of Arotech as a member of such Board, and shall cause the Executive to be elected to, and the Executive shall serve on, the Board of Epsilor-EFL as a member of such Board. For the avoidance of doubt, even if the Executive is not elected to either position, it will not affect any of his rights and responsibilities under this Agreement and he will continue to serve and be employed as a senior officer of the Company.
|
(d)
|
Each Company will use its reasonable best efforts to obtain, and to keep in place at all times that the Executive is a director or officer of either Company, a directors and officers liability policy covering the Executive in an amount and otherwise containing terms and conditions consistent with past practices.
|
(e)
|
The Executive agrees to serve on the board of directors of such subsidiaries of the Companies as the Board may reasonably request.
|
(a)
|
The Companies agree to pay or cause to be paid to the Executive a monthly base salary at the rate of NIS 122,050 per month, or such larger amount as the Board may in its sole discretion determine following a review which shall be conducted by the Board by not later than March 31 of each year (beginning with March 31, 2014), such larger amount to take effect retroactively to the January 1 immediately preceding such review (hereinafter referred to as the “Base Salary”). Notwithstanding such review, on each anniversary of the effective date of this Agreement, the Base Salary shall be adjusted upward in an amount equal to the official anticipated net Israeli inflation rate as published by the Israeli Central Bureau of Statistics in the month of December immediately preceding such anniversary, in each case for the year immediately following such anniversary (the “CPI Adjustment”). For the avoidance of doubt, it is understood by the parties that the monthly base salary stated above shall be not adjusted for 2013, retroactive to January 1, 2013, in respect of the CPI Adjustment for inflation during 2012.
|
(b)
|
The
Companies agree to pay or cause to be paid to the Executive, in a single lump-sum payment in cash on each anniversary of this Agreement or as soon thereafter as may be possible in order to determine the relevant results of the Companies (but in no event later than May 31 of each year), an annual bonus (if and to the extent earned according to the criteria below), as follows:
|
|
(i)
|
If, as of such anniversary, the Company shall have attained 100% of the Company’s Budgeted Number (as defined below) for the year preceding such anniversary, then Executive’s bonus shall be equal to 25% of Executive’s gross annual Base Salary as then in effect for the year preceding such anniversary;
|
|
(ii)
|
If, as of such anniversary, the Companies shall have attained 120% of the Companies’ Budgeted Number (as defined below) for the year preceding such anniversary, then Executive’s bonus shall be equal to 75% of Executive’s annual Base Salary as then in effect for the year preceding such anniversary;
|
|
(iii)
|
If, as of such anniversary, the Companies shall have attained more than 100% but less than 120% of the Companies’ Budgeted Number (as defined below), then Executive’s bonus shall be calculated as follows:
|
(c)
|
In addition, the Companies shall pay Executive an amount of up to $10,000, against invoices or receipts, on each anniversary of this Agreement to cover Executive’s tax and financial planning expenses.
|
(d)
|
The Companies agree to pay to the Executive the Retirement Payment (as defined under Section 7(b)(ii) of the Original Agreement), consisting of the following elements, less taxes and other customary withholdings, if any, as follows:
|
|
(i)
|
By transfer to the Executive of share certificate AC 0563 n/o “
Ella Benita Advocate as trustee for Robert S. Ehrlich”
in the amount of 328,767 shares of Arotech common stock
(the “Shares”) upon the signing of this Agreement
(it having been previously agreed between the parties by letter dated April 19,2009 that the issuance and now the transfer of the Shares to the Executive would be a credit against the Retirement Payment in the amount of $240,000, irrespective of any changes in the market value of the Shares).
|
|
(ii)
|
$774,377 of the Retirement Payment shall be paid to the Executive
in cash upon the signing of this Agreement, said payment to be equal to and withdrawn from
the principal of the Exec
utive’s Rabbi Trust established by trust agreement dated December 23, 2003
.
|
|
(iii)
|
The remaining $611,023 of the Retirement Payment will be paid to the Executive in 30 equal monthly installments of $20,367.43 each on or before the last day of each calendar month by wire transfer to an account to be specified in writing by the Executive, beginning with the calendar month of May 2013 through and including the calendar month of October 2015.
|
(a)
|
Manager’s Insurance
. The Executive and the Companies agree that notwithstanding any prior practice or custom, the Executive will not receive manager’s insurance benefits, including without limitation disability and life insurance.
|
(b)
|
Education Fund (Keren Hishtalmut)
. The Companies will contribute to an education fund of the Executive’s choice an amount equal to 7.5% of each monthly payment of the Base Salary (up to the maximum amount of the Base Salary as to which contributions to an education fund may be made without any tax being due on such contribution by the Executive (the “Education Fund Maximum”)), and will deduct from each monthly payment of the Base Salary and contribute to such education fund an additional amount equal to 2.5% of each such monthly payment of the Base Salary (up to an amount equal to 1/3 of the Education Fund Maximum). Upon the termination of the Executive’s employment with the Companies for whatever reason, including without limitation termination for Cause or the resignation by the Executive, the right to receive any amounts in such fund shall be automatically assigned to the Executive.
|
(c)
|
Vacation
. The Executive shall be entitled to an annual vacation at full pay equal to 24 work days.
|
(d)
|
Sick Leave
. The Executive shall be entitled to up to 30 days of fully paid sick leave annually;
provided
,
however
, that the Executive shall not be entitled to sick leave payment to the extent he is already covered by manager’s insurance. Sick leave may be accumulated and at the conclusion of this Agreement for all reasons other than Cause, up to 30 days of accumulated but unused sick leave shall be converted into a cash payment to the Executive in an amount equal to the proportionate part of the Base Salary for such days.
|
(e)
|
Automobile
. The Executive and the Companies agree that notwithstanding any prior practice or custom, the Companies shall not provide the Executive with an automobile. The Company will continue to pay the maintenance and fuel expenses for the Executive’s personal automobile as it has in the past.
|
(f)
|
Recuperation Payments (D’mai Havra-ah)
. The Executive shall be entitled to Recuperation Payments as required by law.
|
(g)
|
Benefit Plans
. The Executive shall be entitled to participate in all stock-based incentive, bonus, benefit or other similar plans offered by either of the Companies, including without limitation Arotech’s 2009 Equity Incentive Plan, in accordance with the terms thereof and as determined by the Boards from time to time.
|
(a)
|
Death
. This Agreement shall terminate upon the death of the Executive.
|
(b)
|
Disability
. The Companies may terminate the Executive’s employment after having established the Executive’s Disability. For purposes of this Agreement, “Disability” means a physical or mental infirmity which impairs the Executive’s ability to substantially perform his duties under this Agreement which continues for a period of at least one hundred and eighty (180) consecutive days.
|
(c)
|
Cause
. The Companies may terminate the Executive’s employment for Cause. For purposes of this Agreement, termination for “Cause” shall mean and include: (i) conviction for fraud, crimes of moral turpitude or other conduct which reflects on the Companies in a material and adverse manner; (ii) a willful failure to carry out a material directive of either of the Boards,
provided
that such directive concerned matters within the scope of the Executive’s duties, was in conformity with Sections 2(a) and 2(b) hereof, would not give the Executive Good Reason to terminate this Agreement and was capable of being reasonably and lawfully performed; (iii) conviction in a court of competent jurisdiction for embezzlement of funds of the Companies; and (iv) reckless or willful misconduct that is materially harmful to either of the Companies;
provided
,
however
, that the Companies may not terminate the Executive for Cause unless they have given the Executive (i) written notice of the basis for the proposed termination given not more than thirty (30) days after the Companies have obtained knowledge of such basis (“Companies’ Notice of Termination”) and (ii) a period of at least thirty (30) days after the Executive’s receipt of such notice in which to cure such basis.
|
(d)
|
Good Reason
. The Executive may terminate his employment under this Agreement for Good Reason. For purposes of this Agreement, “Good Reason” shall mean the occurrence of any of the events or conditions described in subsections (i) through (viii) hereof:
|
|
(i)
|
a change in the Executive’s status, title, position or responsibilities which, in the Executive’s reasonable judgment, represents a reduction or demotion in the Executive’s status, title, position or responsibilities as in effect immediately prior thereto (except for the change in responsibilities and title contemplated by Section 2(a) above), or in the composition of a majority of the Board of Directors;
|
|
(ii)
|
a reduction in the Executive’s Base Salary;
|
|
(iii)
|
the failure by the Companies to continue in effect any material compensation or benefit plan in which the Executive is participating;
|
|
(iv)
|
the insolvency or the filing (by any party, including the Companies) of a petition for the winding-up of either of the Companies;
|
|
(v)
|
any material breach by the Companies of any provision of this Agreement;
|
|
(vi)
|
any purported termination of the Executive’s employment for Cause by the Companies which does not comply with the terms of Section 6(c) of this Agreement;
|
|
(vii)
|
any movement of either Company’s principal executive offices from the Jerusalem/Tel Aviv area of Israel; and
|
|
(viii)
|
any movement of the location where the Executive is generally to render his services to the Companies hereunder from the Jerusalem/Tel Aviv area of Israel;
|
(e)
|
Termination Date, Etc
.
“Termination Date” shall mean in the case of the Executive’s death, his date of death, or in all other cases, the date specified in the Notice of Termination subject to the following:
|
|
(i)
|
if the Executive’s employment is terminated by the Companies for Cause or due to Disability, the date specified in the Companies’ Notice of Termination shall be at least thirty (30) days from the date the Notice of Termination is given to the Executive,
provided
that in the case of Disability the Executive shall not have returned to the full-time performance of his duties during such period of at least thirty (30) days;
|
|
(ii)
|
if the Executive’s employment is terminated for Good Reason, the Termination Date specified in the Executive’s Notice of Termination shall not be more than sixty (60) days from the date the Notice of Termination is given to the Companies.
|
(a)
|
If the Executive’s employment is terminated by the Companies for Cause, or if the Executive’s employment is terminated by the Executive other than with Good Reason, then the Companies shall pay the Executive all amounts of Base Salary and the employee benefits specified in clauses (a), (b) and (c) of Section 4 of this Agreement earned or accrued hereunder through the Termination Date but not paid as of the Termination Date (collectively, “Accrued Compensation”).
|
(b)
|
If the Executive’s employment by the Companies shall be terminated (1) due to Disability, (2) by the Executive for Good Reason, (3) by the Executive’s death, or (4) by this Agreement coming to the end of the Term, then the Executive shall be entitled to the benefits provided below (in addition to and not instead of whatever other benefits he may be entitled to by reason of operation of law):
|
|
(i)
|
The Companies shall pay the Executive (a) all Accrued Compensation, (b) a bonus at the rate that would otherwise be payable pursuant to the provisions of Section 3(b) above for the year in which the Termination Date occurs (based on the Company’s actual results during the full year in which the Termination Date occurs), of Executive’s annual Base Salary as of the Termination Date,
pro rated
based on the number of days in such year which occurred prior to the Termination Date and paid at the time and in the manner specified in Section 3(b) above, (c) the amounts referred to in Section 4(d) above, to the extent earned or accrued hereunder through the Termination Date but unpaid as of the Termination Date, and (d) in the case of termination by the Executive for Good Reason, or termination by the Companies without Cause, all Base Salary that the Executive would have been paid through the end of the Term but for the termination.
|
|
(ii)
|
For thirty-six (36) months after the Executive ceases to be an officer of either of the Companies, the Companies shall at their expense continue to provide the Executive with a cellular telephone, an e-mail account, and an office if the Company or any of its subsidiaries otherwise maintains office space in Beit Shemesh, Israel, or if not then a home office allowance of $1,000 per month. The Executive will also be authorized in his discretion to hire a secretary at a salary of no more than $2,000 per month. The Executive will be solely responsible for any taxes levied on the above benefits.
|
(c)
|
The Companies may procure life insurance on the Executive in order to secure the payment of its obligations arising in the event of termination under Section 6(a) hereof. Such insurance shall be payable to the Company, which shall remain primarily liable for the payment of all such obligations to the Executive.
|
(d)
|
All stock options and restricted stock that are unvested shall vest on termination (except for Termination for Cause). In the event of termination due to any reason except for Termination for Cause, the Executive’s stock options shall be extended for a period of the earlier of (x) the expiration date thereof, and (y) two years after such termination.
|
(e)
|
The Companies and the Executive agree that the Executive currently holds
200,000 unvested
restricted shares of Arotech common stock (the “Restricted Stock”). Of these shares, 100,000 shares are scheduled to vest on December 31, 2013 (33,334 on the basis of time only and 66,666 on the basis of performance criteria); 33,334 shares are scheduled to vest on June 30, 2013 (on the basis of time only); 33,333 shares are scheduled to vest on June 30, 2014 (on the basis of time only); and 33,333 shares are scheduled to vest on June 30, 2015 (on the basis of time only). It is agreed that on termination (except Termination for Cause), any of the Executive’s remaining unvested Restricted Shares shall immediately become unrestricted and freely tradable (subject to applicable securities laws).
|
(a)
|
Confidentiality
. Executive recognizes and acknowledges that the technology, developments, designs, inventions, improvements, data, methods, trade secrets and works of authorship which the Companies own, plan or develop, including without limitation the specifications, documentation and other information relating to the Companies’ zinc-air battery systems, and businesses and equipment related thereto (in each case whether for their own use or for use by their clients) are confidential and are the property of the Companies. Executive also recognizes that the Companies’ technology, customer lists, supplier lists, proposals and procedures are confidential and are the property of the Companies. Executive further recognizes and acknowledges that in order to enable the Companies to perform services for their clients, those clients may furnish to the Companies confidential information concerning their business affairs, property, methods of operation or other data. All of these materials and information will be referred to below as “Proprietary Information”;
provided
,
however
, that such information shall not include any information known generally to the public (other than as a result of unauthorized disclosure by the Executive).
|
(b)
|
Non-Disclosure
. Executive agrees that, except as directed by the Companies, and in the ordinary course of the Companies’ businesses, Executive will not during Executive’s employment with the Companies and thereafter, disclose to any person or entity or use, directly or indirectly for Executive’s own benefit or the benefit of others, any Proprietary Information, or permit any person to examine or make copies of any documents which may contain or be derived from Proprietary Information;
provided
,
however
, that the Executive’s duties under this Section 8(b) shall not extend to (i) any disclosure that may be required by law in connection with any judicial or administrative proceeding or inquiry or (ii) any disclosure which may be reasonably required in connection with any actions or proceedings to enforce the Executive’s rights under this Agreement. Executive agrees that the provisions of this paragraph shall survive the termination of this Agreement and Executive’s employment by the Companies.
|
(c)
|
Competitive Activity
. The Executive undertakes not, directly or indirectly (whether as owner, partner, consultant, employee or otherwise) at any time, during and for sixty (60) months following termination of his employment with the Companies, to engage in or contribute his knowledge to any work or activity that involves a product, process, service or development which is then directly (in any material manner) competitive with the Companies’ businesses as then constituted. Notwithstanding the foregoing, the Executive shall be permitted to engage in the aforementioned proposed work or activity if the Companies furnishes him with written consent to that effect signed by an authorized officer of each Company.
|
(d)
|
No Solicitation
. During the period specified in 8(c) hereof, Executive will not solicit or encourage any customer or supplier of either Company or of any group, division or subsidiary of either Company, to terminate its relationship with either Company or any such group, division or subsidiary, and Executive will not, directly or indirectly, recruit or otherwise seek to induce any employee of either Company or any such group, division or subsidiary to terminate his or her employment or violate any agreement with or duty to either Company or any such group, division or subsidiary.
|
(e)
|
Equitable Relief
. The Executive agrees that violations of the material covenants in this Section 8 will cause the Companies irreparable injuries and agrees that the Companies may enforce said covenants by seeking injunctive or other equitable relief (in addition to any other remedies the Companies may have at law for damages or otherwise) from a court of competent jurisdiction. In the event such court declares these covenants to be too broad to be specifically enforced, the covenants shall be enforced to the largest extent as may be allowed by such court for the Companies’ protection. Executive further agrees that no breach by the Companies of, or other failure by the Companies under this Agreement shall relieve the Executive of any obligations under Sections 8(a) and 8(b) hereof.
|
(a)
|
This Agreement shall be binding upon and shall inure to the benefit of each Company, its successors and assigns and the Companies shall require any successor or assign to expressly assume and agree to perform this Agreement in the same manner and to the same extent that the Companies would be required to perform it if no such succession or assignment had taken place. The term the “Companies” as used herein shall include such successors and assigns. The term “successors and assigns” as used herein shall mean a corporation or other entity acquiring all or substantially all the assets and business of either Company (including this Agreement) whether by operations of law or otherwise.
|
(b)
|
Subject to Section 16 hereof, neither this Agreement nor any right or interest hereunder shall be assignable or transferable by the Executive, his beneficiaries or legal representatives, except by will or by the laws of descent and distribution. This Agreement shall inure to the benefit of and be enforceable by the Executive’s legal personal representative.
|
(a)
|
If Arotech at any time proposes to register any of its securities under the Securities Act of 1933, as from time to time in effect (together with the rules and regulations thereunder, all as from time to time in effect, the “Securities Act”), for its own account or for the account of any holder of its securities, on a form which would permit registration of Common Stock of Arotech at the time held or obtainable upon the exercise of options, warrants or rights, or the conversion of convertible securities, at the time held by the Executive (“Registrable Securities”), for sale to the public under the Securities Act, Arotech will each such time give notice to the Executive of its intention to do so. Such notice shall describe such securities and specify the form, manner and other relevant aspects of such proposed registration. The Executive may, by written response delivered to Arotech within 15 days after the giving of any such notice, request that all or a specified part of the Registrable Securities be included in such registration. Arotech will thereupon use its best efforts as part of its filing of such form to effect the registration under the Securities Act of all Registrable Securities which Arotech has been so requested to register by the Executive, to the extent required to permit the disposition (in accordance with the intended methods thereof as aforesaid) of the Registrable Securities to be so registered.
|
(b)
|
The Executive may, by notice to Arotech specifying the intended method or methods of disposition, given at any time and from time to time after Arotech has registered any shares of its Common Stock under the Securities Act, request that Arotech effect the registration under the Securities Act of all or a specified part of the Registrable Securities;
provided
,
however
, that Arotech shall not be required to effect a registration pursuant to this Section 16(b) unless such registration may be effected on a Form S-3 (or any successor or similar Form); and
provided
,
further
, that each registration pursuant to this Section 16(b) shall cover a number of Registrable Shares equal to not less than 2% of the aggregate number of shares of Arotech Common Stock then outstanding. Arotech will then use its best efforts to effect the registration as promptly as practicable under the Securities Act of the Registrable Securities which Arotech has been requested to register by the Executive pursuant to the Section 16(b).
|
(c)
|
Notwithstanding the provisions of Section 16(b), in the event that Executive has requested pursuant to Section 16(b) that Arotech effect a registration of securities, and (i) the Board of Arotech determines that it would be seriously detrimental to Arotech to effect a registration pursuant to Section 16(b), or (ii) the Board of Arotech determines in good faith that (A) Arotech is in possession of material, non-public information concerning an acquisition, merger, recapitalization, consolidation, reorganization or other material transaction by or of Arotech or concerning pending or threatened litigation and (B) disclosure of such information would jeopardize any such transaction or litigation or otherwise materially harm Arotech, then Arotech shall promptly notify Executive of the occurrence of any of the events described in the foregoing clauses (i) or (ii). Upon the occurrence of any of the events described in clauses (i) or (ii) hereof, Arotech shall be allowed to defer a registration of securities pursuant to Section 16(b) above, and if a registration statement had already been filed at such time, Executive shall not dispose of his Registrable Securities under such registration statement until it is so advised in writing by Arotech that the registration of securities under 16(b) may be effected or resumed. Notwithstanding the foregoing, any such deferment or prohibition on disposition shall not be in effect for more than 90 days in any 12 months period.
|
(d)
|
Arotech shall not be obligated to effect any registration of Registrable Securities under Section 16(a) hereof incidental to the registration of any of its securities in connection with mergers, acquisitions, exchange offers, dividend reinvestment plans or stock option or other employee benefit plans.
|
(e)
|
Arotech hereby agrees to pay, or cause to be paid, all legal, accounting, printing and other expenses (other than the fees and expenses of the Executive’s own counsel and other than underwriting discounts and commissions attributable to the Registrable Securities) in connection with each registration of Registrable Securities pursuant to this Section 16.
|
(f)
|
In connection with each registration of Registrable Securities pursuant to this Section 16, Arotech and the Executive will enter into such agreements, containing such terms and conditions, as are customary in connection with public offerings, such agreements to contain, without limitation, customary indemnification provisions, representations and warranties and opinions and other documents to be delivered in connection therewith, and to be, if requested, with underwriters.
|
(g)
|
The provisions of this Section 16 shall be subject to any agreement entered into by Arotech, in good faith, with any underwriter of Arotech’s securities or any person or entity providing financing to Arotech, in each case containing reasonable limitations on the Executive’s rights and Arotech’s obligations hereunder.
|
(h)
|
The provisions of this Section 16 shall survive the termination of the other provisions of this Agreement. The rights of the Executive under this Section 16 are assignable, in whole or in part, by the Executive to any person or other entity acquiring securities of Arotech from the Executive.
|
(i)
|
Notwithstanding anything in the foregoing to the contrary, the Executive shall not demand a registration during the 180 days following an underwritten public offering of the Common Stock of the Company.
|
(j)
|
Without the prior written consent of the underwriters managing any public offering, for a period beginning ten days immediately preceding the effective date of any registration statement filed by the Company under the Securities Act of 1933, as amended, and ending on the earlier of (i) 180 days after the effective date of such registration statement and (ii) the end of the shortest period generally applicable to any “affiliate” (as defined in the Securities Act of 1933, as amended) of Arotech who is a selling shareholder pursuant to such registration statement or who is otherwise subject to a lockup provision, the Executive (whether or not a selling shareholder pursuant to such registration statement) shall not sell or otherwise transfer any securities of Arotech except pursuant to such registration statement.
|
17.
|
Taxes
.
|
18.
|
Currency
.
|
(a)
|
The Executive shall be employed as President of the Company until September 30, 2014, and thereafter shall be employed as President and Chief Executive Officer of the Company. The Executive shall perform the duties, undertake the responsibilities and exercise the authority customarily performed, undertaken and exercised by persons situated in a similar executive capacity in Israeli subsidiaries of publicly-held corporations. The Executive shall exercise his authority in a reasonable manner and shall report to the Chairman (the “Chairman”) of the Board of Directors (the “Board) of Arotech until September 30, 2014, and thereafter to the Board.
|
(b)
|
Excluding periods of vacation and sick leave to which the Executive shall be entitled, the Executive agrees to devote the attention and time to the businesses and affairs of the Company required to discharge the responsibilities assigned to the Executive hereunder. The Company acknowledges that the Executive is a director of multiple non-profit organizations. In addition, the Company acknowledges that the Executive is involved in certain investment activities which, together with the above mentioned positions, will consume a portion of his time. The Company consents to these other positions and activities so long as these do not interfere in any material manner with the Executive’s performance of his duties hereunder and do not constitute a violation of Section 8 hereof.
|
(c)
|
While the Executive is employed by the Company hereunder, the Company shall use its best efforts to cause the Executive to be elected to the Board of Directors of the Company (the “Board”) and on the board of directors of such of the Company’s affiliates as the Board shall determine, as a member of such Board(s).
|
(d)
|
The Company will use its reasonable best efforts to obtain, and to keep in place at all times that the Executive is a director or officer of the Company, a directors and officers liability policy covering the Executive in an amount and otherwise containing terms and conditions consistent with past practices.
|
(e)
|
The Executive agrees to serve on the Board and on the board of directors of such affiliates of the Company as the Board may request.
|
(f)
|
The Executive shall be required to travel on a periodic basis. Air travel shall be business class.
|
(a)
|
Base Salary
. The Company agrees to pay or cause to be paid to the Executive, for his services to the Company during the Term, a base salary (the “Base Salary”) to be paid by Epsilor at the rate of NIS 74,515 per month, as adjusted upward annually each January (beginning with January 2014) in an amount equal to the official anticipated net Israeli inflation rate as published by the Israeli Central Bureau of Statistics in the month of December prior to such adjustment (the “CPI Adjustment”).
|
(b)
|
Bonus
. The Company agrees to pay or cause to be paid to the Executive, in a single lump-sum payment in cash on each anniversary of this Agreement or as soon thereafter as may be possible in order to determine the relevant results of the Company (but in no event later than May 31 of each year), an annual bonus (if and to the extent earned according to the criteria below), as follows:
|
(i) | If, as of such anniversary, the Company shall have attained 100% of the Company’s Budgeted Number (as defined below) for the year preceding such anniversary, then Executive’s bonus shall be equal to 25% of Executive’s gross annual Base Salary as then in effect for the year preceding such anniversary; | |
(ii) | If, as of such anniversary, the Company shall have attained 120% of the Company’s Budgeted Number (as defined below) for the year preceding such anniversary, then Executive’s bonus shall be equal to 75% of Executive’s gross annual Base Salary as then in effect for the year preceding such anniversary; | |
(iii) | If, as of such anniversary, the Company shall have attained more than 100% but less than 120% of the Company’s Budgeted Number (as defined below), then Executive’s bonus shall be calculated as follows: | |
B = (S x 25%) + (N-100)/20 x (S x 50%) | ||
Where: |
B = The amount of Executive’s annual bonus, as a percentage of Executive’s gross annual Base Salary; and | ||
N = The percentage of the Budgeted Number (as defined below) that was attained by the Company in the immediately preceding fiscal year; provided , however , that N is more than 100 and less than 120; | ||
S = Executive’s gross annual Base Salary. |
(c)
|
Equity Grants
. The Executive will receive annual stock option or restricted stock bonus grants in respect of the common stock of the Company’s parent corporation, Arotech Corporation (“Arotech”), in amounts to be determined based on the recommendation of the Chairman and the decision of the Compensation Committee of Arotech.
|
(d)
|
Tax Planning Reimbursement
. The Company shall pay Executive an amount of up to NIS 45,000 on each anniversary of this Agreement to cover Executive’s legal, tax and financial planning expenses, against invoices or receipts; any excess in any given year may be used by the Executive to fund supplemental health or life insurance policies, if any. Any amounts not used in a given year shall roll over to future years, but amounts unused at notice of termination of this Agreement shall expire. Legal expenses may not be used to finance legal advice or litigation against the interests of the Company.
|
(a)
|
Life and Disability Insurance
. The Company will pay to an insurance company of the Executive’s choice, as premiums for life and disability insurance for the Executive, an amount equal to 13.33% of each monthly payment of the Base Salary together with 2.5% of the Base Salary for disability, and will deduct from each monthly payment of the Base Salary and pay to such insurance company an amount equal to 5% of each monthly payment of the Base Salary, which shall constitute the Executive’s contribution to such premiums. Upon the termination of the Executive’s employment with the Company for whatever reason, including without limitation termination for Cause or the resignation by the Executive, the right to receive the life and disability insurance benefits shall be automatically assigned to the Executive. At the Executive’s option, in lieu of providing life and disability insurance, the Company shall pay the amount it would otherwise pay for such insurance to the trust referred to in Section 7(b)(ii) hereof.
|
(b)
|
Education Fund
. The Company will contribute to an education fund of the Executive’s choice an amount equal to 7.5% of each monthly payment of the Base Salary, and will deduct from each monthly payment of the Base Salary and contribute to such education fund an additional amount equal to 2.5% of each such monthly payment of the Base Salary. Additionally, the Company will pay a supplementary amount to the education fund in the amount of 20% of the Base Salary. Upon the termination of the Executive’s employment with the Company for whatever reason, including without limitation termination for Cause or the resignation by the Executive, the right to receive any amounts in such fund shall be automatically assigned to the Executive. All education fund contributions or imputed income made under this Section in excess of the statutory exemption shall be tax-effected such that the amount of contribution net of any taxes and withholding (including such amounts in respect of payments pursuant to this sentence) equals the percentages specified herein.
|
(c)
|
Vacation
. The Executive shall be entitled to an annual vacation at full pay equal to 24 work days. Vacation days may be accumulated and may, at the Executive’s option or automatically upon termination, be converted into cash payments in an amount equal to the proportionate part of the Base Salary for such days;
provided
,
however
, that if the Executive accumulates more than two (2) times his then current annual entitlement of vacation days, such excess shall be automatically converted into the right to receive such a cash payment in respect of such excess. Payments to which the Executive is entitled pursuant to this Section 4(c) shall be made promptly after the Executive’s request therefor.
|
(d)
|
Sick Leave
. The Executive shall be entitled to a maximum aggregate of 30 days of fully paid sick leave (inclusive of days accrued under the Original Agreement), accruing at the rate of 2.5 days per month;
provided
,
however
, that the Executive shall not be entitled to sick leave payment to the extent he is already covered by manager’s insurance. Sick leave may be accumulated and may, at the Executive’s option, be converted into cash payments in an amount equal to the proportionate part of the Base Salary for such days. Payments to which the Executive is entitled pursuant to this Section 4(d) shall be made promptly after the Executive’s request therefor.
|
(e)
|
Automobile
. Every three years, the Company shall make a new automobile available to the Executive during the term of this Agreement. Such automobile shall be of a high quality comparable to, but not less than, that of a 2012 model Honda Legend, and shall be subject to the approval of the Executive, which shall not be unreasonably withheld. The Executive shall be entitled to use the automobile for his personal and business needs, so long as he does not allow anyone who would not be covered by the Company’s insurance to drive it. The Company shall pay all expenses of maintaining and operating the automobile. All expense reimbursements or imputed income made under this Section shall be tax-effected such that the amount of reimbursement received by the Executive net of any taxes and withholdings (including such amounts in respect of payments pursuant to this sentence) equals the expense incurred.
|
(f)
|
Benefit Plans
. The Executive shall be entitled to participate in all incentive, bonus, benefit or other similar plans offered by the Company, including without limitation the Company’s 2009 Equity Incentive Plan, in accordance with the terms thereof and as determined by the Board from time to time.
|
(g)
|
Medical Insurance
. The Executive shall be entitled to obtain, at Company expense of up to $12,000 per year, medical insurance for himself and his family.
|
(a)
|
Death
. This Agreement shall terminate upon the death of the Executive.
|
(b)
|
Disability
. The Company may terminate the Executive’s employment after having established the Executive’s Disability. For purposes of this Agreement, “Disability” means a physical or mental infirmity which impairs the Executive’s ability to substantially perform his duties under this Agreement which continues for a period of at least one hundred and eighty (180) consecutive days.
|
(c)
|
Cause
. The Company may terminate the Executive’s employment for Cause. For purposes of this Agreement, termination for “Cause” shall mean and include: (i) conviction for fraud, crimes of moral turpitude or other conduct which reflects on the Company in a material and adverse manner; (ii) a willful failure to carry out a material directive of the Board,
provided
that such directive concerned matters within the scope of the Executive’s duties, was in conformity with Sections 2(a) and 2(b) hereof, would not give the Executive Good Reason to terminate this Agreement and was capable of being reasonably and lawfully performed; (iii) conviction in a court of competent jurisdiction for embezzlement of funds of the Company; and (iv) reckless or willful misconduct that is materially harmful to the Company;
provided
,
however
, that the Company may not terminate the Executive for Cause unless they have given the Executive written notice of the basis for the proposed termination (“Company’s Notice of Termination”).
|
(d)
|
Good Reason
. The Executive may terminate his employment under this Agreement for Good Reason. For purposes of this Agreement, “Good Reason” shall mean the occurrence of any of the events or conditions described in subsections (i) through (vi) hereof:
|
|
(i)
|
(1) a change in the Executive’s status, title, position or responsibilities (except for the change in responsibilities and title contemplated by Section 2(a) above) which, in the Executive’s reasonable judgment, represents a reduction or demotion in the Executive’s status, title, position or responsibilities as in effect immediately prior thereto, or (2) a change in the primary location from which the Executive shall have conducted his business activities during the 60 days prior to such change, or (3) a change in the composition of a majority of the Board of Directors, or (4) the failure to promote the Executive to the position of President and Chief Executive Officer on or before October 1, 2014;
|
|
(ii)
|
a reduction in the Executive’s Base Salary;
|
|
(iii)
|
the failure by the Company to continue the Executive as a participant in any material compensation or benefit plan in which the other senior executives of the Company are participating unless agreed to by the Executive;
|
|
(iv)
|
the insolvency or the filing (by any party, including the Company) of a petition for the winding-up of the Company or of Arotech;
|
|
(v)
|
any material breach by the Company of any provision of this Agreement;
|
|
(vi)
|
any purported termination of the Executive’s employment for Cause by the Company which does not comply with the terms of Section 6(c) of this Agreement;
|
(e)
|
Termination Date, Etc.
“Termination Date” shall mean in the case of the Executive’s death, his date of death, or in all other cases, the date specified in the Notice of Termination subject to the following:
|
|
(i)
|
if the Executive’s employment is terminated by the Company for Cause or due to Disability, the date specified in the Company’s Notice of Termination shall be at least thirty (30) days from the date the Notice of Termination is given to the Executive,
provided
that in the case of Disability the Executive shall not have returned to the full-time performance of his duties during such period of at least thirty (30) days;
|
|
(ii)
|
if the Executive’s employment is terminated for Good Reason, the Termination Date specified in the Executive’s Notice of Termination shall not be more than sixty (60) days from the date the Notice of Termination is given to the Company.
|
(f)
|
Retirement
. At any time during the period beginning (i) 150 days prior to his 65th birthday (“Retirement”) or (ii) from 150 days prior to his 55th birthday until 150 days prior to his 65th birthday (“Early Retirement”), the Executive may retire from his positions with the Companies by giving to the Companies written Notice of Retirement specifying the Retirement Date, which Retirement Date shall be at least one hundred and fifty (150) days from the date of such Notice of Retirement.
|
(g)
|
Termination Without Cause
. Termination other than as set forth above shall constitute termination “Without Cause.”
|
(a)
|
If the Executive’s employment is terminated by the Company for Cause or if the Executive’s employment is terminated by the Executive Without Cause, then the Company shall pay the Executive all amounts of Base Salary and the employee benefits specified in clauses (a), (b) and (c) of Section 4 of this Agreement earned or accrued hereunder through the Termination Date but not paid as of the Termination Date (collectively, “Accrued Compensation”).
|
(b)
|
If the Executive’s employment by the Company shall be terminated (1) due to Disability, (2) by the Executive for Good Reason, (3) by the Executive’s death, (4) due to this Agreement coming to the end of the Term and not being extended or immediately succeeded by a new substantially similar employment agreement (“Non-Renewal”), (5) due to Retirement or Early Retirement, or (6) by the Company Without Cause, then the Executive shall be entitled to the additional benefits provided below, which, in the case of death, Disability, Retirement or Early Retirement, shall be in lieu of any further salary for periods subsequent to the Termination Date):
|
|
(i)
|
The Company shall pay the Executive (a) all Accrued Compensation, (b) a bonus at a rate of the higher of (i) 20%, or (ii) the rate that would otherwise be payable pursuant to the provisions of Section 3(b) above for the year in which the Termination Date occurs, of Executive’s annual Base Salary as of the Termination Date,
pro rated
based on the number of days in such year which occurred prior to the Termination Date, (c) the amounts referred to in Sections 4(d) and (e) above, to the extent earned or accrued hereunder through the Termination Date but unpaid as of the Termination Date, and (d) in the case of termination by the Executive for Good Reason, or termination by the Companies without Cause, all Base Salary that the Executive would have been paid through the end of the Term but for the termination;
|
|
(ii)
|
The Company shall pay into a trust to be established pursuant to a separate trust agreement or shall purchase a certificate of deposit registered in the Executive’s name but held by the Company (the “Trust”) as termination pay and in lieu of any further salary for periods subsequent to the Termination Date (except as provided in Section 7(b)(i) above), an amount equal to the higher of (i) twenty-four (24) times the monthly Base Salary at the highest rate in effect at any time within the ninety (90) day period ending on the Termination Date, and (ii) NIS 3,144,000 (the “Base Termination Pay”). Base Termination Pay will vest and be funded into the Trust as provided in Section 7(b)(iv) below. The parties agree, pursuant to the terms of the letter between the parties dated April 19, 2009, that the payment of $200,000 of the Base Termination Pay shall be accomplished by transfer to the Executive of share certificate AC 0564 n/o “Ella Benita Advocate as trustee for Steven Esses” in the amount of 273,973 shares of Arotech common stock (the “Shares”) (it having been previously agreed between the parties that the issuance and now the transfer of the Shares to the Executive would be a credit against the Base Termination Pay in the amount of $200,000, irrespective of any changes of any changes in the market value of the Shares).
|
|
(iii)
|
The Company shall pay to the Executive, in respect of all benefits, an additional sum in the amount of (i) $75,000, in the case of Termination due to Disability, the Executive’s death, or Non-Renewal, or (ii) $150,000, in the case of Termination due to Early Retirement, Retirement, or Good Reason. Additionally, the Company shall transfer to the Executive title to the Honda Legend currently in the possession of the Executive, upon payment by the Executive to the Company, in advance, of all taxes that the Company in good faith believes will be due and owing as a result of the transfer of such title.
|
|
(iv)
|
In the event of a termination by the Company without Cause or by the Executive due to Good Reason, all of the Executive’s stock options, whether or not they have yet vested, shall immediately vest and shall be extended for a period of the later of (x) the expiration date thereof, and (y) the second anniversary of such termination, and all of the Executive’s restricted stock shall immediately become unrestricted and freely tradable (subject to applicable securities laws). In the event of termination due to any other reason except for Termination for Cause, the Executive’s then-vested stock options shall be extended for a period of the earlier of (x) the expiration date thereof, and (y) two years after such termination.
|
(c)
|
If the Executive’s employment by the Company shall be terminated by the Executive for the reason specified in Section 6(d)(i)(3) above, then in addition to the sums otherwise payable hereunder, the Executive shall be paid an amount equal to the product of (x) NIS 20,645, multiplied by (y) the number (which need not be a whole number) of months between January 1, 2013 and the date of such termination, which result shall be multiplied by (z) 1.16.
|
8.
|
Confidentiality; Proprietary Rights; Competitive Activity
.
|
(a)
|
Confidentiality
. Executive recognizes and acknowledges that the technology, developments, designs, inventions, improvements, data, methods, trade secrets and works of authorship which the Company owns, plans or develops, including without limitation the specifications, documentation and other information relating to the Company’s zinc-air battery systems, and businesses and equipment related thereto (in each case whether for their own use or for use by their clients) are confidential and are the property of the Company. Executive also recognizes that the Company’s technology, customer lists, supplier lists, proposals and procedures are confidential and are the property of the Company. Executive further recognizes and acknowledges that in order to enable the Company to perform services for its clients, those clients may furnish to the Company confidential information concerning their business affairs, property, methods of operation or other data. All of these materials and information will be referred to below as “Proprietary Information”;
provided
,
however
, that such information shall not include any information known generally to the public (other than as a result of unauthorized disclosure by the Executive).
|
(b)
|
Non-Disclosure
. Executive agrees that, except as directed by the Company, and in the ordinary course of the Company’s business, Executive will not during Executive’s employment with the Company and thereafter, disclose to any person or entity or use, directly or indirectly for Executive’s own benefit or the benefit of others, any Proprietary Information, or permit any person to examine or make copies of any documents which may contain or be derived from Proprietary Information;
provided
,
however
, that the Executive’s duties under this Section 8(b) shall not extend to (i) any disclosure that may be required by law in connection with any judicial or administrative proceeding or inquiry or (ii) any disclosure which may be reasonably required in connection with any actions or proceedings to enforce the Executive’s rights under this Agreement. Executive agrees that the provisions of this paragraph shall survive the termination of this Agreement and Executive’s employment by the Company.
|
(c)
|
Competitive Activity
. The Executive undertakes not, directly or indirectly (whether as owner, partner, consultant, employee or otherwise) at any time, during and for twelve (12) months following termination of his employment with the Company, to engage in or contribute his knowledge to any work or activity that involves a product, process, service or development which is then directly (in any material manner) competitive with any business that the Company has conducted during the term of this Agreement or any extension hereof on which the Executive worked or with respect to which the Executive had access to Proprietary Information while with the Company. Notwithstanding the foregoing, the Executive shall be permitted to engage in the aforementioned proposed work or activity if the Company furnishes him with written consent to that effect signed by an authorized officer of the Company.
|
(d)
|
No Solicitation
. During the period specified in 8(c) hereof, Executive will not solicit or encourage any customer or supplier of the Company or of any group, division or subsidiary of the Company, to terminate its relationship with the Company or any such group, division or subsidiary, and Executive will not, directly or indirectly, recruit or otherwise seek to induce any employee of the Company or any such group, division or subsidiary to terminate his or her employment or violate any agreement with or duty to the Company or any such group, division or subsidiary.
|
(e)
|
Equitable Relief
. The Executive agrees that violations of the material covenants in this Section 8 will cause the Company irreparable injuries and agrees that the Company may enforce said covenants by seeking injunctive or other equitable relief (in addition to any other remedies the Company may have at law for damages or otherwise) from a court of competent jurisdiction. In the event such court declares these covenants to be too broad to be specifically enforced, the covenants shall be enforced to the largest extent as may be allowed by such court for the Company’s protection. Executive further agrees that no breach by the Company of, or other failure by the Company under this Agreement shall relieve the Executive of any obligations under Sections 8(a) and 8(b) hereof.
|
9.
|
Successors and Assigns
.
|
(a)
|
This Agreement shall be binding upon and shall inure to the benefit of the Company, its successors and assigns and the Company shall require any successor or assign to expressly assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession or assignment had taken place. The term the “Company” as used herein shall include such successors and assigns. The term “successors and assigns” as used herein shall mean a corporation or other entity acquiring all or substantially all the assets and business of the Company (including this Agreement) whether by operations of law or otherwise.
|
(b)
|
Neither this Agreement nor any right or interest hereunder shall be assignable or transferable by the Executive, his beneficiaries or legal representatives, except by will or by the laws of descent and distribution. This Agreement shall inure to the benefit of and be enforceable by the Executive’s legal personal representative.
|
(c)
|
Nothing to the contrary in the foregoing notwithstanding, the Executive may assign this Agreement to any company of which he is a “control person” within the meaning of the Securities Exchange Act of 1934,
provided
, that the Executive shall continue to be obligated to fulfill the duties set forth in Section 2 above, and
provided
,
further
, that the Executive shall continue to be bound by the terms and provisions of Section 8 of this Agreement notwithstanding any such assignment.
|
10.
|
Notice
.
|
|
The Company:
|
Arotech Corporation and Epsilor-Electric Fuel Ltd.
|
|
The Executive:
|
Steven Esses
|
11.
|
Miscellaneous
.
|
12.
|
Governing Law; Arbitration; Venue
.
|
13.
|
Severability
.
|
14.
|
Entire Agreement
.
|
15.
|
Registration Rights
.
|
(a)
|
If the Company at any time proposes to register any of its securities under the Securities Act of 1933, as from time to time in effect (together with the rules and regulations thereunder, all as from time to time in effect, the “Securities Act”), for its own account or for the account of any holder of its securities, on a form which would permit registration of Common Stock of the Company at the time held or obtainable upon the exercise of options, warrants or rights, or the conversion of convertible securities, at the time held by the Executive (“Registrable Securities”), for sale to the public under the Securities Act, the Company will each such time give notice to the Executive of its intention to do so. Such notice shall describe such securities and specify the form, manner and other relevant aspects of such proposed registration. The Executive may, by written response delivered to the Company within 15 days after the giving of any such notice, request that all or a specified part of the Registrable Securities be included in such registration. the Company will thereupon use its best efforts as part of its filing of such form to effect the registration under the Securities Act of all Registrable Securities which the Company has been so requested to register by the Executive, to the extent required to permit the disposition (in accordance with the intended methods thereof as aforesaid) of the Registrable Securities to be so registered.
|
(b)
|
The Executive may, by notice to the Company specifying the intended method or methods of disposition, given at any time and from time to time after the Company has registered any shares of its Common Stock under the Securities Act, request that the Company effect the registration under the Securities Act of all or a specified part of the Registrable Securities;
provided
,
however
, that the Company shall not be required to effect a registration pursuant to this Section 15(b) unless such registration may be effected on a Form S-3 (or any successor or similar Form); and
provided
,
further
, that each registration pursuant to this Section 15(b) shall cover a number of Registrable Shares equal to not less than 2% of the aggregate number of shares of the Company Common Stock then outstanding. the Company will then use its best efforts to effect the registration as promptly as practicable under the Securities Act of the Registrable Securities which the Company has been requested to register by the Executive pursuant to the Section 15(b).
|
(c)
|
Notwithstanding the provisions of Section 15(b), in the event that Executive has requested pursuant to Section 15(b) that the Company effect a registration of securities, and (i) the Board determines that it would be seriously detrimental to the Company to effect a registration pursuant to Section 15(b), or (ii) the Board determines in good faith that (A) the Company is in possession of material, non-public information concerning an acquisition, merger, recapitalization, consolidation, reorganization or other material transaction by or of the Company or concerning pending or threatened litigation and (B) disclosure of such information would jeopardize any such transaction or litigation or otherwise materially harm the Company, then the Company shall promptly notify Executive of the occurrence of any of the events described in the foregoing clauses (i) or (ii). Upon the occurrence of any of the events described in clauses (i) or (ii) hereof, the Company shall be allowed to defer a registration of securities pursuant to Section 15(b) above, and if a registration statement had already been filed at such time, Executive shall not dispose of his Registrable Securities under such registration statement until it is so advised in writing by the Company that the registration of securities under 15(b) may be effected or resumed. Notwithstanding the foregoing, any such deferment or prohibition on disposition shall not be in effect for more than 90 days in any 12 months period.
|
(d)
|
The Company shall not be obligated to effect any registration of Registrable Securities under Section 15(a) hereof incidental to the registration of any of its securities in connection with mergers, acquisitions, exchange offers, dividend reinvestment plans or stock option or other employee benefit plans.
|
(e)
|
The Company hereby agrees to pay, or cause to be paid, all legal, accounting, printing and other expenses (other than the fees and expenses of the Executive’s own counsel and other than underwriting discounts and commissions attributable to the Registrable Securities) in connection with each registration of Registrable Securities pursuant to this Section 15.
|
(f)
|
In connection with each registration of Registrable Securities pursuant to this Section 15, the Company and the Executive will enter into such agreements, containing such terms and conditions, as are customary in connection with public offerings, such agreements to contain, without limitation, customary indemnification provisions, representations and warranties and opinions and other documents to be delivered in connection therewith, and to be, if requested, with underwriters.
|
(g)
|
The provisions of this Section 15 shall be subject to any agreement entered into by the Company, in good faith, with any underwriter of the Company’s securities or any person or entity providing financing to the Company, in each case containing reasonable limitations on the Executive’s rights and the Company’s obligations hereunder.
|
(h)
|
The provisions of this Section 15 shall survive the termination of the other provisions of this Agreement. The rights of the Executive under this Section 16 are assignable, in whole or in part, by the Executive to any person or other entity acquiring securities of the Company from the Executive.
|
(i)
|
Notwithstanding anything in the foregoing to the contrary, the Executive shall not demand a registration during the 180 days following an underwritten public offering of the Common Stock of the Company.
|
(j)
|
Without the prior written consent of the underwriters managing any public offering, for a period beginning ten days immediately preceding the effective date of any registration statement filed by the Company under the Securities Act of 1933, as amended, and ending on the earlier of (i) 180 days after the effective date of such registration statement and (ii) the end of the shortest period generally applicable to any “affiliate” (as defined in the Securities Act of 1933, as amended) of the Company who is a selling shareholder pursuant to such registration statement or who is otherwise subject to a lockup provision, the Executive (whether or not a selling shareholder pursuant to such registration statement) shall not sell or otherwise transfer any securities of the Company except pursuant to such registration statement.
|
16.
|
Taxes
.
|
17.
|
Currency
.
|
Epsilor-Electric Fuel Ltd.
By:
/s/ Ronen Badichi
Name: Ronen Badichi
Title: General Manager
|
/s/ Steven Esses
Steven Esses
|
|
Arotech Corporation
By:
/s/ Robert S. Ehrlich
Name: Robert S. Ehrlich
Title: Chairman and CEO
|
Epsilor-Electric Fuel Ltd.
By:
Name:
Title:
|
Steven Esses
|
|
Arotech Corporation
1229 Oak Valley Drive
Ann Arbor, Michigan 48108
Tel: (800) 281-0356 Fax: (734) 761-5368
http://www.arotech.com
Nasdaq National Market: ARTX
Writer’s direct dial:
+972-2-990-6612
Writer’s direct fax:
+972-2-990-6688
Writer’s e-mail:
ehrlich@arotech.com
|
Robert S. Ehrlich
Chairman and Chief Executive Officer
|
|
(i)
|
Upon the death of the Executive, unless Sampen provides a new individual who is acceptable to the Company to serve in that position.
|
|
(ii)
|
Upon the Disability of the Executive, unless Sampen provides a new individual who is acceptable to the Company to serve in that position. For purposes of this Agreement, “Disability” means a physical or mental infirmity which impairs the Executive’s ability to substantially perform Sampen’s duties under this Agreement which continues for a period of at least one hundred and eighty (180) consecutive days.
|
|
(iii)
|
For “Cause,” which shall mean and include: (i) conviction for fraud, crimes of moral turpitude or other conduct which reflects on the Company in a material and adverse manner; (ii) a willful failure to carry out a material directive of the Board,
provided
that such directive concerned matters within the scope of Sampen’s duties, was in conformity with Section 1(b) hereof, would not give Sampen Good Reason to terminate this Agreement and was capable of being reasonably and lawfully performed; (iii) conviction in a court of competent jurisdiction for embezzlement of funds of the Company; and (iv) reckless or willful misconduct that is materially harmful to the Company;
provided
,
however
, that the Company may not terminate Sampen for Cause unless it has given Sampen written notice of the basis for the proposed termination (“Company’s Notice of Termination”).
|
|
(i)
|
For “Good Reason,” which shall mean and include:
|
|
(A)
|
a change (1) in the Executive’s status, title, position or responsibilities which, in Sampen’s reasonable judgment, represents a reduction or demotion in the Executive’s status, title, position or responsibilities as in effect immediately prior thereto, or (2) in the primary location from which Sampen shall have conducted its business activities under this Agreement during the 60 days prior to such change;
|
|
(B)
|
a reduction in Sampen’s Base Payment (as hereinafter defined);
|
|
(C)
|
the insolvency or the filing (by any party, including the Company) of a petition for the winding-up of the Company;
|
|
(D)
|
any material breach by the Company of any provision of this Agreement; and
|
|
(E)
|
any purported termination of this Agreement for Cause by the Company which does not comply with the terms of Section 2(c)(iii) of this Agreement;
|
|
(ii)
|
if there is a “Change in Control” in Arotech. For purposes of this Agreement, a “Change in Control” shall mean any of the following events:
|
(A)
|
The dissolution or liquidation of the Company;
|
(B)
|
A merger, consolidation, reorganization or similar transaction involving the Company (a) in which the Company is not the surviving corporation or other surviving entity, or (b) that results in the Company becoming a subsidiary of another corporation (a “Transaction”);
|
(C)
|
A sale or other disposition of all or substantially all of the assets of the Company to another corporation or other entity, as determined in accordance with the applicable law of the State of Delaware;
|
(D)
|
Any other transaction (including a merger, consolidation, reorganization or similar transaction) that results in any corporation or other entity beneficially owning (within the meaning of Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) immediately following the consummation of such transaction (a) in the case of voting securities acquired other than directly from the Company, more than 20% of the voting securities of the Company, or (b) in the case of voting securities acquired directly from the Company, more than 50% of the voting securities of the Company; or
|
(E)
|
The members of the Board of Directors of the Company on the date of this letter (the “Incumbent Board Members”) ceasing for any reason to constitute (a) at any time prior to the consummation of a Transaction, a majority of the Board, or (b) at any time following the consummation of a Transaction, a majority of the board of directors or other governing body of the corporation or other entity whose voting securities are issued to existing stockholders of the Company in such Transaction;
provided
,
however
, that any individual becoming a member of the Board or of such board of directors or other governing body, as the case may be, subsequent to the date of this Agreement whose appointment or nomination for election was approved by a vote of at least a majority of the Incumbent Board Members shall be deemed to be an Incumbent Board Member for purposes of this clause (v), but excluding, for such purposes, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors (or other members of any such governing body) or other actual or threatened solicitation of proxies or contests by or on behalf of a person other than the Board or such board of directors or other governing body, as the case may be.
|
|
(iii)
|
if there is a “Change of Location.” For purposes of this Agreement, a “Change of Location” shall mean a change of more than 100 kilometers in the primary location from which the business activities of the Executive shall have been conducted during the 60 days prior to such change.
|
|
(i)
|
If this Agreement is terminated by the Company for Cause or due to Disability, the date specified in the Company’s Notice of Termination shall be at least thirty (30) days from the date the Notice of Termination is given to Sampen,
provided
that in the case of Disability the Executive shall not have returned to the full-time performance of its duties during such period of at least thirty (30) days assuming Sampen cannot provide a substitute Executive acceptable to the Company; and
|
|
(ii)
|
If this Agreement is terminated for Good Reason, or because there has been a Change in Control, the Termination Date specified in Sampen’s Notice of Termination shall not be more than sixty (60) days from the date the Notice of Termination is given to the Company.
|
|
(i)
|
A base payment at the rate of US $8,960 per month, or such larger amount as the Compensation Committee of the Board (the “Compensation Committee) may in its sole discretion determine following a review which shall be conducted by the Board and the Compensation Committee by not later than March 31 of each year, such larger amount to take effect retroactively to the January 1 immediately preceding such review (hereinafter referred to as the “Base Payment”). Such Base Payment shall be payable in equal monthly installments.
|
|
(ii)
|
On each anniversary of this Agreement or as soon thereafter as may be possible in order to determine the relevant results of the Company, (but in no event later than May 31 of each year), in a single lump-sum payment in cash, an annual bonus (if and to the extent earned according to the criteria below), as follows:
|
|
(A)
|
If, as of such anniversary, Arotech shall have attained 100% of Arotech’s Budgeted Number (as defined below) for the year preceding such anniversary, then Sampen’s bonus shall be equal to 25% of Sampen’s gross annual Base Payment as then in effect for the year preceding such anniversary;
|
|
(B)
|
If, as of such anniversary, Arotech shall have attained 120% of Arotech’s Budgeted Number (as defined below) for the year preceding such anniversary, then Sampen’s bonus shall be equal to 75% of Sampen’s gross annual Base Payment as then in effect for the year preceding such anniversary;
|
|
(C)
|
If, as of such anniversary, Arotech shall have attained more than 100% but less than 120% of Arotech’s Budgeted Number (as defined below), then Sampen’s bonus shall be calculated as follows:
|
|
(i)
|
The Company will pay Sampen, to cover the cost of the Company’s use of Sampen’s office as an ancillary Company office and insurance, an amount equal to 16% of each monthly payment of the Base Payment.
|
|
(ii)
|
The Company agrees that Sampen shall provide the Executive with an annual vacation at full pay equal to 24 work days. Vacation days may be accumulated and may, at the Executive’s option or automatically upon termination, be converted into cash payments in an amount equal to the proportionate part of the Base Payment for such days;
provided
,
however
, that if the Executive accumulates more than two (2) times its then current annual entitlement of vacation days, such excess shall be automatically converted into the right to receive such a cash payment in respect of such excess. Payments to which Sampen is entitled pursuant to this Section 3(b)(ii) shall be made promptly after Sampen’s request therefore.
|
|
(iii)
|
Sampen shall provide the Executive with a maximum aggregate of 30 days of fully paid sick leave, accruing at the rate of 2.5 days per month. Sick leave may be accumulated and may, at Sampen’s option, be converted into cash payments in an amount equal to the proportionate part of the Base Payment for such days. Payments to which Sampen is entitled pursuant to this Section 3(b)(iii) shall be made promptly after Sampen’s request therefor.
|
|
B =
|
The amount of Employee’s annual bonus; and
|
|
N =
|
The percentage of the Budgeted Number (as defined below) that was attained by the Company in the immediately preceding fiscal year;
provided
,
however
, that N is more than 100 and less than 120;
|
|
S =
|
Employee’s gross annual Base Salary.
|
/s/ Thomas J. Paup
Thomas J. Paup
|
Arotech Corporation
By:
/s/ Robert S. Ehrlich
Name: Robert S. Ehrlich
Title: Chairman and CEO
|
|
(a)
|
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
|
|
(b)
|
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
|
(c)
|
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this quarterly report based on such evaluation; and
|
|
(d)
|
disclosed in this quarterly report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
|
(a)
|
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
|
(b)
|
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.
|
/s/ Robert S. Ehrlich
|
|
Robert S. Ehrlich, Chairman and CEO
|
|
(Principal Executive Officer)
|
/s/ Thomas J. Paup
|
|
Thomas J. Paup, Vice President – Finance and CFO
|
|
(Principal Financial Officer)
|
/s/ Robert S. Ehrlich
|
|
Robert S. Ehrlich, Chairman and CEO
|
|
(Principal Executive Officer)
|
/s/ Thomas J. Paup
|
|
Thomas J. Paup, Vice President – Finance and CFO
|
|
(Principal Financial Officer)
|